Degradation and stabilization of peptide hormones in human blood specimens

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Yi, Jizu ^a   Warunek, David ^a   Craft, David ^a  

^a BD Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV; EDETIC ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; OXYNTOMODULIN; PEPTIDE HORMONE; DPP4 PROTEIN, HUMAN; GASTRIC INHIBITORY POLYPEPTIDE; PEPTIDE FRAGMENT;

AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN; HUMAN EXPERIMENT; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NORMAL HUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN STABILITY; ROOM TEMPERATURE; AMINO ACID SEQUENCE; BLOOD; GENETICS; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; DIPEPTIDYL PEPTIDASE 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MOLECULAR SEQUENCE DATA; OXYNTOMODULIN; PEPTIDE FRAGMENTS; PEPTIDE HORMONES; PROTEIN STABILITY; PROTEOLYSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84941702911     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134427     Document Type: Article

References (57)

1. Holst J, Ørskov C. In: Walsh J, Dockray G, editors. Gut peptides: biochemistry and physiology. New York: Raven Press; 1994. p. 305-40.
2. Stanley S, Wynne K, McGowan B, Bloom S. Hormonal regulation of food intake. Physiol Rev. 2005; 85 (4): 1131-58. Epub 2005/09/27. 85/4/1131 [pii] doi: 10.1152/physrev.00015.2004 PMID: 16183909.
3. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6): 2131-57. Epub 2007/05/15. S0016-5085(07)00580-X [pii] doi: 10.1053/j.gastro.2007.03.054 PMID: 17498508.
4. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009; 297(1-2): 127-36. Epub 2008/09/13. doi: 10.1016/j.mce.2008.08.012 S0303-7207 (08)00362-6 [pii]. PMID: 18786605.
5. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008; 60(4): 470-512. Epub 2008/12/17. doi: 10.1124/pr.108.000604 pr.108.000604 [pii]. PMID: 19074620; PubMed Central PMCID: PMC2696340.
6. Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005; 31(3 Pt 1): 233-42. Epub 2005/09/06. MDOI-DM-06-2005-31-3-1262-3636-101019-200514505 [pii]. PMID: 16142014.
7. Nauck M, Smith U. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients? Best Pract Res Clin Endocrinol Metab. 2009; 23(4): 513-23. Epub 2009/09/15. doi: 10.1016/j.beem.2009.03.002 S1521-690X(09)00021-9 [pii]. PMID: 19748068.
8. Garber AJ. Incretin therapy-present and future. Rev Diabet Stud. 2011; 8(3): 307-22. Epub 2012/01/21. doi: 10.1900/RDS.2011.8.307 PMID: 22262069; PubMed Central PMCID: PMC3280666.
9. Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci. 2013; 7: 181. Epub 2013/10/18. doi: 10.3389/fnins.2013.00181 PMID: 24133407; PubMed Central PMCID: PMC3796262.
10. Maida A, Lovshin JA, Baggio LL, Drucker DJ. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology. 2008; 149(11): 5670-8. Epub 2008/08/02. doi: 10.1210/en.2008-0336 en.2008-0336 [pii]. PMID: 18669601.
11. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003; 88(10): 4696-701. Epub 2003/10/15. doi: 10.1210/jc.2003-030421 PMID: 14557443.
12. Bhat VK, Kerr BD, Flatt PR, Gault VA. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem Pharmacol. 2013; 85(11): 1655-62. Epub 2013/03/23. doi: 10.1016/j.bcp.2013.03.009 S0006-2952(13)00190-1 [pii]. PMID: 23518155.
13. Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009; 296(3): E415-21. Epub 2009/01/01. doi: 10.1152/ajpendo. 90887.2008 90887.2008 [pii]. PMID: 19116373.
14. White CM. A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol. 1999; 39(5): 442-7. Epub 1999/05/11. PMID: 10234590.
15. Kolb A, Rieder S, Born D, Giese NA, Giese T, Rudofsky G, et al. Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus. Cancer Biol Ther. 2009; 8 (16): 1527-33. Epub 2009/07/03. 9006 [pii]. PMID: 19571666.
16. Hewage CM, Venneti KC. Structural aspects of gut peptides with therapeutic potential for type 2 diabetes. ChemMedChem. 2013; 8(4): 560-7. Epub 2013/01/08. doi: 10.1002/cmdc.201200445 PMID: 23292985.
17. Greco V, Pieragostino D, Piras C, Aebersold R, Wiltfang J, Caltagirone C, et al. Direct analytical sample quality assessment for biomarker investigation: qualifying cerebrospinal fluid samples. Proteomics. 2014; 14(17-18): 1954-62. doi: 10.1002/pmic.201300565 PMID: 25044759.
18. Pieragostino D, Petrucci F, Del Boccio P, Mantini D, Lugaresi A, Tiberio S, et al. Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. Journal of proteomics. 2010; 73(3): 579-92. doi: 10.1016/j.jprot.2009.07.014 PMID: 19666151.
19. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics. 2005; 5(13): 3262-77. Epub 2005/07/30. doi: 10.1002/pmic.200401245 PMID: 16052621.
20. Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics. 2006; 3(4): 409-26. Epub 2006/08/12. doi: 10.1586/14789450.3.4.409 PMID: 16901200.
21. Percy AJ, Parker CE, Borchers CH. Pre-analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies. Bioanalysis. 2013; 5(22): 2837-56. Epub 2013/11/22. doi: 10. 4155/bio.13.245 PMID: 24256362.
22. Yi J, Kim C, Gelfand CA. Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res. 2007; 6(5): 1768-81. Epub 2007/04/07. doi: 10.1021/pr060550h PMID: 17411080.
23. Yi J, Liu Z, Craft D, O'Mullan P, Ju G, Gelfand CA. Intrinsic peptidase activity causes a sequential multistep reaction (SMSR) in digestion of human plasma peptides. J Proteome Res. 2008; 7(12): 5112-8. Epub 2009/04/16. doi: 10.1021/pr800396c PMID: 19367699.
24. Craft D, Yi J, Gelfand CA. Time-Dependent and Sample-to-Sample Variations in Human Plasma Peptidome are Both Minimized Through Use of Protease Inhibitors. Analytical Letters. 2009; 42(10): 1398-406.
25. Findeisen P, Sismanidis D, Riedl M, Costina V, Neumaier M. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem. 2005; 51(12): 2409-11. Epub 2005/11/25. 51/12/2409 [pii] doi: 10.1373/clinchem.2005.054585 PMID: 16306114.
26. Karsan A, Eigl BJ, Flibotte S, Gelmon K, Switzer P, Hassell P, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem. 2005; 51(8): 1525-8. Epub 2005/06/14. clinchem.2005.050708 [pii] doi: 10.1373/clinchem.2005.050708 PMID: 15951319.
27. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem. 2008; 54(1): 44-52. Epub 2007/11/06. clinchem.2007.091470 [pii] doi: 10.1373/clinchem.2007.091470 PMID: 17981926; PubMed Central PMCID: PMC3354530.
28. Bystrom CE, Salameh W, Reitz R, Clarke NJ. Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin Chem. 2010; 56(10): 1561-9. Epub 2010/08/27. doi: 10.1373/clinchem.2010.146449 clinchem.2010.146449 [pii]. PMID: 20739638.
29. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004; 36(11-12): 761-5. Epub 2005/01/19. doi: 10.1055/s-2004-826160 PMID: 15655705.
30. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem. 2003; 278(25): 22418-23. Epub 2003/04/12. doi: 10.1074/jbc.M212355200 M212355200 [pii]. PMID: 12690116.
31. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999; 85(1): 9-24. Epub 1999/12/10. S0167-0115(99)00089-0 [pii]. PMID: 10588446.
32. Kervran A, Dubrasquet M, Blache P, Martinez J, Bataille D. Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney. Regul Pept. 1990; 31(1): 41-52. Epub 1990/10/29. 0167-0115(90)90194-2 [pii]. PMID: 2270317.
33. Hinke SA, Pospisilik JA, Demuth HU, Mannhart S, Kuhn-Wache K, Hoffmann T, et al. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J Biol Chem. 2000; 275(6): 3827-34. Epub 2000/02/08. PMID: 10660533.
34. Yi J, Craft D, Gelfand CA. Minimizing preanalytical variation of plasma samples by proper blood collection and handling. Methods Mol Biol. 2011; 728: 137-49. Epub 2011/04/07. doi: 10.1007/978-1-61779-068-3-8 PMID: 21468945.
35. Carles-Bonnet C, Martinez J, Jarrousse C, Aumelas A, Niel H, Bataille D. H-Lys-Arg-Asn-Lys-Asn-Asn-OH is the minimal active structure of oxyntomodulin. Peptides. 1996; 17(3): 557-61. Epub 1996/01/01. 0196-9781(96)00001-0 [pii]. PMID: 8735987.
36. Yi J, Liu Z, Gelfand CA, Craft D. Investigation of peptide biomarker stability in plasma samples using time-course MS analysis. Methods Mol Biol. 2011; 728: 161-75. Epub 2011/04/07. doi: 10.1007/978-1-61779-068-3-10 PMID: 21468947.
37. Wettergren A, Pridal L, Wojdemann M, Holst JJ. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul Pept. 1998; 77(1-3): 83-7. Epub 1998/11/11. S0167-0115(98)00044-5 [pii]. PMID: 9809800.
38. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab. 2009; 23(4): 443-52. Epub 2009/09/15. doi: 10. 1016/j.beem.2009.03.005 S1521-690X(09)00024-4 [pii]. PMID: 19748062.
39. Troutt JS, Siegel RW, Chen J, Sloan JH, Deeg MA, Cao G, et al. Dual-monoclonal, sandwich immunoassay specific for glucose-dependent insulinotropic peptide1-42, the active form of the incretin hormone. Clin Chem. 2011; 57(6): 849-55. Epub 2011/04/26. doi: 10.1373/clinchem.2010.159954 clinchem.2010.159954 [pii]. PMID: 21515744.
40. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000; 85(10): 3575-81. Epub 2000/11/04. doi: 10.1210/jcem.85.10.6855 PMID: 11061504.
41. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993; 214(3): 829-35. Epub 1993/06/15. PMID: 8100523.
42. Thoma R, Loffler B, Stihle M, Huber W, Ruf A, Hennig M. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure. 2003; 11(8): 947-59. Epub 2003/08/09. S0969212603001606 [pii]. PMID: 12906826.
43. Sharma R, McDonald TS, Eng H, Limberakis C, Stevens BD, Patel S, et al. In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. Drug Metab Dispos. 2013; 41(12): 2148-57. Epub 2013/09/24. doi: 10. 1124/dmd.113.054254 dmd.113.054254 [pii]. PMID: 24056839.
44. McDonald TJ, Perry MH, Peake RW, Pullan NJ, O'Connor J, Shields BM, et al. EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperature. PLoS One. 2012; 7(7): e42084. Epub 2012/08/04. doi: 10.1371/journal.pone.0042084 PONE-D-12-06472 [pii]. PMID: 22860060; PubMed Central PMCID: PMC3408407.
45. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002; 34 (12): 1508-12. Epub 2002/10/16. S1357272502000754 [pii]. PMID: 12379270.
46. Santoprete A, Capito E, Carrington PE, Pocai A, Finotto M, Langella A, et al. DPP-IV-resistant, longacting oxyntomodulin derivatives. J Pept Sci. 2011; 17(4): 270-80. Epub 2011/02/05. doi: 10.1002/psc. 1328 PMID: 21294225.
47. Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J, et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res. 2005; 4(3): 972-81. Epub 2005/06/15. doi: 10.1021/pr050046x PMID: 15952745.
48. Blache P, Kervran A, Martinez J, Bataille D. Development of an oxyntomodulin/glicentin C-terminal radioimmunoassay using a "thiol-maleoyl" coupling method for preparing the immunogen. Anal Biochem. 1988; 173(1): 151-9. Epub 1988/08/15. 0003-2697(88)90172-8 [pii]. PMID: 3189794.
49. Thim L, Moody AJ. The primary structure of porcine glicentin (proglucagon). Regul Pept. 1981; 2 (2): 139-50. Epub 1981/05/01. PMID: 6894800.
50. Rogatsky E, Stein DT. Two-dimensional reverse phase-reverse phase chromatography: A simple and robust platform for sensitive quantitative analysis of peptides by LC/MS. Hardware design. J Sep Sci. 2006; 29(4): 538-46. Epub 2006/04/06. PMID: 16583692.
51. van den Broek I, Niessen WM, van Dongen WD. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 929: 161-79. Epub 2013/05/21. doi: 10.1016/j.jchromb.2013.04.030 S1570-0232(13)00241-9 [pii]. PMID: 23685427.
52. Razavi M, Frick LE, LaMarr WA, Pope ME, Miller CA, Anderson NL, et al. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J Proteome Res. 2012; 11(12): 5642-9. Epub 2012/11/07. doi: 10.1021/pr300652v PMID: 23126378.
53. Zhang H, Xin B, Caporuscio C, Olah TV. Bioanalytical strategies for developing highly sensitive liquid chromatography/tandem mass spectrometry based methods for the peptide GLP-1 agonists in support of discovery PK/PD studies. Rapid Commun Mass Spectrom. 2011; 25(22): 3427-35. Epub 2011/10/18. doi: 10.1002/rcm.5241 PMID: 22002697.
54. Halquist MS, Sakagami M, Karnes HT. Determination of oxyntomodulin, an anorectic polypeptide, in rat plasma using 2D-LC-MS/MS coupled with ion pair chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 903: 102-11. Epub 2012/07/31. doi: 10.1016/j.jchromb.2012.06.047 S1570-0232(12)00403-5 [pii]. PMID: 22841744.
55. Miyachi A, Murase T, Yamada Y, Osonoi T, Harada K. Quantitative analytical method for determining the levels of gastric inhibitory polypeptides GIP1-42 and GIP3-42 in human plasma using LC-MS/MS/MS. J Proteome Res. 2013; 12(6): 2690-9. Epub 2013/04/24. doi: 10.1021/pr400069f PMID: 23607762.
56. Siskos AP, Katsila T, Balafas E, Kostomitsopoulos N, Tamvakopoulos C. Simultaneous absolute quantification of the glucose-dependent insulinotropic polypeptides GIP1-42 and GIP3-42 in mouse plasma by LC/ESI-MS/MS: preclinical evaluation of DP-IV inhibitors. J Proteome Res. 2009; 8(7): 3487-96. Epub 2009/05/12. doi: 10.1021/pr900155h PMID: 19425608.
57. Li YX, Hackman M, Wang CY. Quantitation of polypeptides (glucagon and salmon calcitonin) in plasma samples by 'high resolution' on a triple quadrupole mass spectrometer. Bioanalysis. 2012; 4(6): 685-91. Epub 2012/03/29. doi: 10.4155/bio.12.12 PMID: 22452259.